Free Trial
NASDAQ:ABVX

ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis

ABIVAX Société Anonyme logo
$6.16 -0.07 (-1.12%)
As of 01/17/2025 04:00 PM Eastern

About ABIVAX Société Anonyme Stock (NASDAQ:ABVX)

Key Stats

Today's Range
$6.01
$6.23
50-Day Range
$6.15
$10.33
52-Week Range
$5.54
$17.02
Volume
56,917 shs
Average Volume
200,283 shs
Market Capitalization
$390.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.67
Consensus Rating
Buy

Company Overview

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
43rd Percentile Overall Score

ABVX MarketRank™: 

ABIVAX Société Anonyme scored higher than 43% of companies evaluated by MarketBeat, and ranked 656th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ABIVAX Société Anonyme has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    ABIVAX Société Anonyme has only been the subject of 2 research reports in the past 90 days.

  • Read more about ABIVAX Société Anonyme's stock forecast and price target.
  • Earnings Growth

    Earnings for ABIVAX Société Anonyme are expected to grow in the coming year, from ($2.98) to ($2.86) per share.

  • Price to Book Value per Share Ratio

    ABIVAX Société Anonyme has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ABIVAX Société Anonyme's valuation and earnings.
  • Percentage of Shares Shorted

    1.55% of the float of ABIVAX Société Anonyme has been sold short.
  • Short Interest Ratio / Days to Cover

    ABIVAX Société Anonyme has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in ABIVAX Société Anonyme has recently increased by 47.89%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ABIVAX Société Anonyme does not currently pay a dividend.

  • Dividend Growth

    ABIVAX Société Anonyme does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.55% of the float of ABIVAX Société Anonyme has been sold short.
  • Short Interest Ratio / Days to Cover

    ABIVAX Société Anonyme has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in ABIVAX Société Anonyme has recently increased by 47.89%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ABIVAX Société Anonyme has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for ABIVAX Société Anonyme this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added ABIVAX Société Anonyme to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ABIVAX Société Anonyme's insider trading history.
Receive ABVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter.

ABVX Stock News Headlines

Short Interest in ABIVAX Société Anonyme (NASDAQ:ABVX) Rises By 47.9%
Wall St turns to THIS catalyst after Trump’s inauguration
Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger than his inauguration. As soon as January 29th…
See More Headlines

ABVX Stock Analysis - Frequently Asked Questions

ABIVAX Société Anonyme's stock was trading at $7.32 at the start of the year. Since then, ABVX stock has decreased by 15.8% and is now trading at $6.16.
View the best growth stocks for 2025 here
.

ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share.

Top institutional investors of ABIVAX Société Anonyme include GAMMA Investing LLC (0.01%).

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ABIVAX Société Anonyme investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), G1 Therapeutics (GTHX) and Howard Hughes (HHH).

Company Calendar

Today
1/20/2025
Next Earnings (Estimated)
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABVX
Previous Symbol
NASDAQ:ABVX
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.67
High Stock Price Target
$50.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+527.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.37 per share

Miscellaneous

Free Float
N/A
Market Cap
$390.24 million
Optionable
Not Optionable
Beta
0.53
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:ABVX) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners